Close Menu

NEW YORK (GenomeWeb) - GenMark Diagnostics said today it has received 510(k) clearance from the US Food and Drug Administration for a panel assay to detect gram-negative bacteria in blood cultures.

The ePlex Blood Culture Identification Gram-Negative (BCID-GN) Panel detects 21 gram-negative bacteria, six resistance genes, and pan targets for gram-positive organisms and Candida, according to the firm's website. It completes GenMark's suite of multiplex panels to detect bloodstream infections that can cause sepsis, the firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.